Yiming Cao1, Sara Shahrestani, Hong Chee Chew, Michael Crawford, Peter Simon Macdonald, Jerome Laurence, Wayne John Hawthorne, Kumud Dhital, Henry Pleass. 1. 1 Faculty of Medicine, University of New South Wales, NSW, Australia. 2 Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia. 3 Sydney Medical School, University of Sydney, NSW, Australia. 4 Cardiac Transplant Unit, St Vincent's Hospital, Darlinghurst, NSW, Australia. 5 Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 6 RPA Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 7 Department of Surgery, Westmead Hospital, Westmead, NSW, Australia.
Abstract
BACKGROUND: Liver transplantation using donation after circulatory death (DCD) donors is associated with inferior outcomes compared to donation after brain death (DBD). Prolonged donor warm ischemic time has been identified as the key factor responsible for this difference. Various aspects of the donor life support withdrawal procedure, including location of withdrawal and administration of antemortem heparin, are thought to play important roles in mitigating the effects of warm ischemia. However, a systematic exploration of these factors is important for more confident integration of these practices into a standard DCD protocol. METHODS: Medline, EMBASE, and Cochrane libraries were systematically searched and 23 relevant studies identified for analysis. Donation after circulatory death recipients were stratified according to location of life support withdrawal (intensive care unit or operating theater) and use of antemortem heparin. RESULTS: Donation after circulatory death recipients had comparable 1-year patient survival to DBD recipients if the location of withdrawal of life support was the operating theater, but not if the location was the intensive care unit. Likewise, the inferior 1-year graft survival and higher incidence of ischemic cholangiopathy of DCD compared with DBD recipients were improved by withdrawal in operating theater, although higher rates of ischemic cholangiopathy and worse graft survival were still observed in DCD recipients. Furthermore, administering heparin before withdrawal of life support reduced the incidence of primary nonfunction of the allograft. CONCLUSIONS: Our evidence suggests that withdrawal in the operating theater and premortem heparin administration improve DCD liver transplant outcomes, thus allowing for the most effective usage of these valuable organs.
BACKGROUND: Liver transplantation using donation after circulatory death (DCD) donors is associated with inferior outcomes compared to donation after brain death (DBD). Prolonged donor warm ischemic time has been identified as the key factor responsible for this difference. Various aspects of the donor life support withdrawal procedure, including location of withdrawal and administration of antemortem heparin, are thought to play important roles in mitigating the effects of warm ischemia. However, a systematic exploration of these factors is important for more confident integration of these practices into a standard DCD protocol. METHODS: Medline, EMBASE, and Cochrane libraries were systematically searched and 23 relevant studies identified for analysis. Donation after circulatory death recipients were stratified according to location of life support withdrawal (intensive care unit or operating theater) and use of antemortem heparin. RESULTS: Donation after circulatory death recipients had comparable 1-year patient survival to DBD recipients if the location of withdrawal of life support was the operating theater, but not if the location was the intensive care unit. Likewise, the inferior 1-year graft survival and higher incidence of ischemic cholangiopathy of DCD compared with DBD recipients were improved by withdrawal in operating theater, although higher rates of ischemic cholangiopathy and worse graft survival were still observed in DCD recipients. Furthermore, administering heparin before withdrawal of life support reduced the incidence of primary nonfunction of the allograft. CONCLUSIONS: Our evidence suggests that withdrawal in the operating theater and premortem heparin administration improve DCD liver transplant outcomes, thus allowing for the most effective usage of these valuable organs.
Authors: Nicholas Murphy; Charles Weijer; Jennifer Chandler; Frédérick D'Aragon; Andrew Healey; Matthew J Weiss; Marat Slessarev Journal: Can J Anaesth Date: 2022-07-13 Impact factor: 6.713
Authors: Beatriz Domínguez-Gil; Nancy Ascher; Alexander M Capron; Dale Gardiner; Alexander R Manara; James L Bernat; Eduardo Miñambres; Jeffrey M Singh; Robert J Porte; James F Markmann; Kumud Dhital; Didier Ledoux; Constantino Fondevila; Sarah Hosgood; Dirk Van Raemdonck; Shaf Keshavjee; James Dubois; Andrew McGee; Galen V Henderson; Alexandra K Glazier; Stefan G Tullius; Sam D Shemie; Francis L Delmonico Journal: Intensive Care Med Date: 2021-02-26 Impact factor: 17.440
Authors: Leif A Havton; Natalia P Biscola; Esther Stern; Plamen V Mihaylov; Chandrashekhar A Kubal; John M Wo; Anita Gupta; Elizabeth Baronowsky; Matthew P Ward; Deborah M Jaffey; Terry L Powley Journal: Sci Rep Date: 2021-12-13 Impact factor: 4.379